Endoprosthetic_replacement_for_stage_IIB_osteosarcoma._Over_an_eight-year_period,_100_patients_with_IIB_osteosarcoma_have_been_managed._Eighty-one_were_treated_with_limb-salvage_procedures,_78_of_which_involved_reconstruction_utilizing_endoprostheses._Only_19_patients_received_amputation_as_the_primary_treatment_for_local_control._Since_1984,_all_patients_received_preoperative_and_post-operative_adjuvant_chemotherapy._Those_patients_who_received_chemotherapy_had_a_statistically_significant_improvement_in_five-year_survival_over_those_who_did_not_(57%_and_32%,_respectively,_p_=_0.014)._The_functional_results_were_good_overall,_with_excellent_results_seen_in_distal_femoral_reconstruction._Twenty-eight_of_the_78_patients_treated_with_endoprosthetic_reconstruction_experienced_30_complications_(36%)._Mechanical_failure_was_the_most_common_complication_(10%)_but_was_generally_correctable._The_local_recurrence_rate_was_5%_and_the_infection_rate_was_3%._Local_complications_were_manageable._A_statistical_analysis_revealed_that_the_relative_risk_of_patient_death_was_2.5_times_higher_than_prosthesis_failure_for_the_78_patients_with_endoprosthetic_reconstruction._The_intermediate-term_results,_with_a_median_follow-up_period_of_43_months,_remains_encouraging.